Pfizer And BioNTech Claim COVID-19 Vaccine Success
Interim Analysis Finds Vaccine 90% Effective, EUA Filing Expected Late November
Executive Summary
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.
You may also be interested in...
Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead
CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.
Pfizer Pilots COVID-19 Immunization Plan In Four States As ‘Dry Run’
The company's Phase III COVID-19 vaccine trial has reached the needed safety data required for filing an emergency use authorization with the FDA, Bourla confirmed at the Stat Summit.
US COVID-19 Fraud: FTC Points To Peptides As Latest Scam, Silver Remedy Firm Shut Down
FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.
Need a specific report? 1000+ reports available
Buy Reports